

# Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

Information for the public

Published: 20 April 2022

[www.nice.org.uk](http://www.nice.org.uk)

Niraparib (Zejula) is available on the NHS as a possible treatment for relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in adults. It is recommended if:

- they have a BRCA mutation and have had 2 courses of platinum-based chemotherapy that has worked, or
- they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy that has worked.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Ovarian Cancer Action](#), 0207 380 1730
- [Target Ovarian Cancer](#), 0207 923 5475
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4379-1